Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), ...

ICI unmet need through differentiated, biomarker-guided therapies, strategic pipeline prioritization, competitive benchmarking, and market access planning across the 7MM.Dublin, Sept. 30, 2026 (GLOBE ...

Pfizer Canada and BioNTech announced Health Canada’s approval of the Omicron XFG‑adapted COMIRNATY vaccine for individuals ...

Agenus is now a pure-play on its BOT/BAL cancer immunotherapy, with all resources focused on the upcoming ROBBIN Phase 3 ...

The antibody targets patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

COMPASSION-37 will compare cadonilimab plus chemotherapy against chemotherapy with or without nivolumab as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction ...

Immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies have transformed the treatment of many cancers, yet ...

Akeso, Inc. (9926.HK), a biopharmaceutical company, announced that it has enrolled the first patient in COMPASSION-37 (AK104-311), a phase 3 trial evaluating Cadonilimab as first-line treatment for ...

AstraZeneca announced a $2 billion strategic investment in Summit Therapeutics, subscribing to convertible preferred shares at $18.36 per share—an ...

An engineered oncolytic vaccinia virus that combines direct tumour lysis with a built-in gene-silencing payload has emerged ...